Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 5297 | 1110813-31-4 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 4, 2019 | EMA | PFIZER EUROPE MA EEIG | |
Sept. 27, 2018 | FDA | PFIZER INC |
None
None
Source | Code | Description |
---|---|---|
ATC | L01EB07 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:74440 | egfr inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Non-small cell lung cancer, positive for epidermal growth factor receptor expression | indication | 426964009 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.02 | acidic |
pKa2 | 9.12 | Basic |
pKa3 | 4.78 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
15MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2023 | NEW CHEMICAL ENTITY |
30MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2023 | NEW CHEMICAL ENTITY |
45MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2023 | NEW CHEMICAL ENTITY |
15MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2025 | FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
15MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2025 | INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
30MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2025 | FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
30MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2025 | INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
45MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2025 | FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
45MG | VIZIMPRO | PFIZER | N211288 | Sept. 27, 2018 | RX | TABLET | ORAL | Sept. 27, 2025 | INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Epidermal growth factor receptor | Kinase | INHIBITOR | IC50 | 8.22 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Receptor tyrosine-protein kinase erbB-2 | Kinase | INHIBITOR | IC50 | 7.34 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Receptor tyrosine-protein kinase erbB-4 | Kinase | INHIBITOR | IC50 | 7.13 | SCIENTIFIC LITERATURE | DRUG LABEL |
ID | Source |
---|---|
1042385-75-0 | SECONDARY_CAS_RN |
4037910 | VANDF |
C2987430 | UMLSCUI |
CHEBI:132268 | CHEBI |
1C9 | PDB_CHEM_ID |
CHEMBL2105719 | ChEMBL_ID |
CHEMBL2110732 | ChEMBL_ID |
DB11963 | DRUGBANK_ID |
D09883 | KEGG_DRUG |
C525726 | MESH_SUPPLEMENTAL_RECORD_UI |
11511120 | PUBCHEM_CID |
7422 | IUPHAR_LIGAND_ID |
5092U85G58 | UNII |
2058849 | RXNORM |
293963 | MMSL |
35285 | MMSL |
d08999 | MMSL |
017767 | NDDF |
781492009 | SNOMEDCT_US |
781495006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Vizimpro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0197 | TABLET, FILM COATED | 15 mg | ORAL | NDA | 28 sections |
Vizimpro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-1198 | TABLET, FILM COATED | 30 mg | ORAL | NDA | 28 sections |
Vizimpro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-2299 | TABLET, FILM COATED | 45 mg | ORAL | NDA | 28 sections |
Vizimpro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-197 | TABLET, FILM COATED | 15 mg | ORAL | NDA | 27 sections |